359 related articles for article (PubMed ID: 27601850)
1. Nanostructured Lipid Carriers Loaded with Baicalin: An Efficient Carrier for Enhanced Antidiabetic Effects.
Shi F; Wei Z; Zhao Y; Xu X
Pharmacogn Mag; 2016; 12(47):198-202. PubMed ID: 27601850
[TBL] [Abstract][Full Text] [Related]
2. Sucrose ester stabilized solid lipid nanoparticles and nanostructured lipid carriers. I. Effect of formulation variables on the physicochemical properties, drug release and stability of clotrimazole-loaded nanoparticles.
Das S; Ng WK; Tan RB
Nanotechnology; 2014 Mar; 25(10):105101. PubMed ID: 24531790
[TBL] [Abstract][Full Text] [Related]
3. Are nanostructured lipid carriers (NLCs) better than solid lipid nanoparticles (SLNs): development, characterizations and comparative evaluations of clotrimazole-loaded SLNs and NLCs?
Das S; Ng WK; Tan RB
Eur J Pharm Sci; 2012 Aug; 47(1):139-51. PubMed ID: 22664358
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation.
Dudhipala N; Janga KY; Gorre T
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):616-625. PubMed ID: 29688077
[TBL] [Abstract][Full Text] [Related]
5. Preparation, characterization and pharmacokinetic studies of linalool-loaded nanostructured lipid carriers.
Shi F; Zhao Y; Firempong CK; Xu X
Pharm Biol; 2016 Oct; 54(10):2320-8. PubMed ID: 26986932
[TBL] [Abstract][Full Text] [Related]
6. Preparation of Ergosterol-Loaded Nanostructured Lipid Carriers for Enhancing Oral Bioavailability and Antidiabetic Nephropathy Effects.
Dong Z; Iqbal S; Zhao Z
AAPS PharmSciTech; 2020 Jan; 21(2):64. PubMed ID: 31932990
[TBL] [Abstract][Full Text] [Related]
7. Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers.
Wei Q; Yang Q; Wang Q; Sun C; Zhu Y; Niu Y; Yu J; Xu X
AAPS PharmSciTech; 2018 Nov; 19(8):3661-3669. PubMed ID: 30324361
[TBL] [Abstract][Full Text] [Related]
8. Lipid-based nano-formulation platform for eplerenone oral delivery as a potential treatment of chronic central serous chorioretinopathy:
Abd-Elhakeem E; El-Nabarawi M; Shamma R
Drug Deliv; 2021 Dec; 28(1):642-654. PubMed ID: 33787445
[TBL] [Abstract][Full Text] [Related]
9. Transdermal delivery of allopurinol-loaded nanostructured lipid carrier in the treatment of gout.
Ali Z; Din FU; Zahid F; Sohail S; Imran B; Khan S; Malik M; Zeb A; Khan GM
BMC Pharmacol Toxicol; 2022 Nov; 23(1):86. PubMed ID: 36443818
[TBL] [Abstract][Full Text] [Related]
10. Enhanced circulation longevity and pharmacodynamics of metformin from surface-modified nanostructured lipid carriers based on solidified reverse micellar solutions.
Kenechukwu FC; Isaac GT; Nnamani DO; Momoh MA; Attama AA
Heliyon; 2022 Mar; 8(3):e09100. PubMed ID: 35313488
[TBL] [Abstract][Full Text] [Related]
11. Formulation, optimization, and in vitro evaluation of nanostructured lipid carriers for topical delivery of Apremilast.
Madan JR; Khobaragade S; Dua K; Awasthi R
Dermatol Ther; 2020 May; 33(3):e13370. PubMed ID: 32250507
[TBL] [Abstract][Full Text] [Related]
12. Preparation and Characterization of Minoxidil Loaded Nanostructured Lipid Carriers.
Wang W; Chen L; Huang X; Shao A
AAPS PharmSciTech; 2017 Feb; 18(2):509-516. PubMed ID: 27120090
[TBL] [Abstract][Full Text] [Related]
13. Implications of formulation design on lipid-based nanostructured carrier system for drug delivery to brain.
Salunkhe SS; Bhatia NM; Bhatia MS
Drug Deliv; 2016 May; 23(4):1306-16. PubMed ID: 25080227
[TBL] [Abstract][Full Text] [Related]
14. Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks.
Elmowafy M; Ibrahim HM; Ahmed MA; Shalaby K; Salama A; Hefesha H
Drug Deliv; 2017 Nov; 24(1):932-941. PubMed ID: 28617150
[TBL] [Abstract][Full Text] [Related]
15. Effect of liquid-to-solid lipid ratio on characterizations of flurbiprofen-loaded solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs) for transdermal administration.
Song A; Zhang X; Li Y; Mao X; Han F
Drug Dev Ind Pharm; 2016 Aug; 42(8):1308-14. PubMed ID: 26707734
[TBL] [Abstract][Full Text] [Related]
16. Nose to Brain Delivery of Astaxanthin-Loaded Nanostructured Lipid Carriers in Rat Model of Alzheimer's Disease: Preparation, in vitro and in vivo Evaluation.
Shehata MK; Ismail AA; Kamel MA
Int J Nanomedicine; 2023; 18():1631-1658. PubMed ID: 37020692
[TBL] [Abstract][Full Text] [Related]
17. Lipids-based nanostructured lipid carriers (NLCs) for improved oral bioavailability of sirolimus.
Yu Q; Hu X; Ma Y; Xie Y; Lu Y; Qi J; Xiang L; Li F; Wu W
Drug Deliv; 2016 May; 23(4):1469-75. PubMed ID: 27187522
[TBL] [Abstract][Full Text] [Related]
18. Improvement of oral bioavailability of lovastatin by using nanostructured lipid carriers.
Zhou J; Zhou D
Drug Des Devel Ther; 2015; 9():5269-75. PubMed ID: 26425076
[TBL] [Abstract][Full Text] [Related]
19. Optimized Nanoparticles for Enhanced Oral Bioavailability of a Poorly Soluble Drug: Solid Lipid Nanoparticles Versus Nanostructured Lipid Carriers.
Darwish MKM; El-Enin ASMA; Mohammed KHA
Pharm Nanotechnol; 2022; 10(1):69-87. PubMed ID: 35142275
[TBL] [Abstract][Full Text] [Related]
20. Quality by design (QbD)-based fabrication of atazanavir-loaded nanostructured lipid carriers for lymph targeting: bioavailability enhancement using chylomicron flow block model and toxicity studies.
Gurumukhi VC; Bari SB
Drug Deliv Transl Res; 2022 May; 12(5):1230-1252. PubMed ID: 34110597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
